| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.9M | — | +166.1% |
| Cost of Revenue | $7.5M | — | +121.1% |
| R&D Expense | $85K | — | -41.0% |
| SG&A Expense | $3.2M | — | +168.5% |
| Operating Income | -$3.6M | — | -159.2% |
| Interest Expense | $89K | — | — |
| Pre-tax Income | -$6.2M | — | -264.6% |
| Net Income | -$6.2M | — | -264.6% |
| EPS (Basic) | -$6.81 | — | -3905.9% |
| EPS (Diluted) | -$6.81 | — | -3905.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.3M | -43.4% | -36.8% |
| Accounts Receivable | $8.4M | +304.2% | +338.8% |
| Current Assets | $18.9M | +43.7% | +92.0% |
| Total Assets | $80.2M | +252.6% | +580.2% |
| Current Liabilities | $21.0M | +64.1% | +554.4% |
| Long-term Debt | $8.5M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$6.9M | — | -23.5% |
| Capital Expenditures | $22K | — | — |
| Investing Cash Flow | -$6.0M | — | — |
| Financing Cash Flow | $9.5M | — | -23.3% |
| Free Cash Flow | -$6.9M | — | — |
| — |
| Total Liabilities | $27.5M | +114.7% | +756.1% |
| Stockholders' Equity | $52.7M | +429.9% | +514.4% |